The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|3|5|349-358

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.3, Iss.5, 2003-10, pp. : 349-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on Hsp90 Inhibitors in Clinical Trial

By  

Current Topics in Medicinal Chemistry, Vol. 9, Iss. 15, 2009-11 ,pp. : 1479-1492

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and development of purine-scaffold Hsp90 inhibitors

By Chiosis Gabriela   Kang Yanlong   Sun Weilin  

Expert Opinion on Drug Discovery, Vol. 3, Iss. 1, 2008-01 ,pp. : 99-114

Informa Healthcare

Access to resources Recommend Favorite

Discovery and Development of Pyrazole-Scaffold Hsp90 Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 11, 2006-06 ,pp. : 1193-1203

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Development of Purine-Scaffold Hsp90 Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 6, Iss. 11, 2006-01 ,pp. : 1183-1191

Bentham Science Publishers

Access to resources Recommend Favorite

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

By  

Current Pharmaceutical Design, Vol. 19, Iss. 3, 2013-01 ,pp. : 366-376

Bentham Science Publishers

Access to resources Recommend Favorite